Appendix 2—table 38. Antidiabetic User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non users.
| All Antidiabetic Users by BP: Unmatched | All Antidiabetic Users by BP: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | BP Non-user | BP User | p-value | All | BP Non-user | BP User | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 754,553 | 100.0% | 674,024 | 89.3% | 80,529 | 10.7% | 159,000 | 100.0% | 79,500 | 50.0% | 79,500 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 6,211 | 0.8% | 6,169 | 0.9% | 42 | 0.1% | <0.001 | 83 | 0.1% | 41 | 0.1% | 42 | 0.1% | 1.00 |
| 21-40 | 57,725 | 7.7% | 57,535 | 8.5% | 190 | 0.2% | 380 | 0.2% | 190 | 0.2% | 190 | 0.2% | ||
| 41-50 | 91,905 | 12.2% | 90,952 | 13.5% | 953 | 1.2% | 1,905 | 1.2% | 952 | 1.2% | 953 | 1.2% | ||
| 51-60 | 191,194 | 25.3% | 182,922 | 27.1% | 8,272 | 10.3% | 16,536 | 10.4% | 8,268 | 10.4% | 8,268 | 10.4% | ||
| 61-70 | 207,434 | 27.5% | 180,895 | 26.8% | 26,539 | 33.0% | 53,028 | 33.4% | 26,512 | 33.3% | 26,516 | 33.4% | ||
| 71-80 | 138,309 | 18.3% | 107,467 | 15.9% | 30,842 | 38.3% | 60,240 | 37.9% | 30,121 | 37.9% | 30,119 | 37.9% | ||
| ≥81 | 61,775 | 8.2% | 48,084 | 7.1% | 13,691 | 17.0% | 26,828 | 16.9% | 13,416 | 16.9% | 13,412 | 16.9% | ||
| Gender | ||||||||||||||
| Female | 458,459 | 60.8% | 386,400 | 57.3% | 72,059 | 89.5% | <0.001 | 142,068 | 89.4% | 71,027 | 89.3% | 71,041 | 89.4% | 0.91 |
| Male | 296,094 | 39.2% | 287,624 | 42.7% | 8,470 | 10.5% | 16,932 | 10.6% | 8,473 | 10.7% | 8,459 | 10.6% | ||
| Region | ||||||||||||||
| Midwest | 134,022 | 17.8% | 123,909 | 18.4% | 10,113 | 12.6% | <0.001 | 20,168 | 12.7% | 10,084 | 12.7% | 10,084 | 12.7% | 1.00 |
| Northeast | 217,040 | 28.8% | 196,723 | 29.2% | 20,317 | 25.2% | 40,446 | 25.4% | 20,223 | 25.4% | 20,223 | 25.4% | ||
| South | 289,781 | 38.4% | 257,599 | 38.2% | 32,182 | 40.0% | 63,740 | 40.1% | 31,870 | 40.1% | 31,870 | 40.1% | ||
| West | 113,710 | 15.1% | 95,793 | 14.2% | 17,917 | 22.2% | 34,646 | 21.8% | 17,323 | 21.8% | 17,323 | 21.8% | ||
| Insurance | ||||||||||||||
| Commercial | 307,023 | 40.7% | 290,957 | 43.2% | 16,066 | 20.0% | <0.001 | 32,086 | 20.2% | 16,043 | 20.2% | 16,043 | 20.2% | 1.00 |
| Dual | 42,606 | 5.6% | 32,797 | 4.9% | 9,809 | 12.2% | 18,653 | 11.7% | 9,321 | 11.7% | 9,332 | 11.7% | ||
| Medicaid | 206,868 | 27.4% | 188,638 | 28.0% | 18,230 | 22.6% | 35,513 | 22.3% | 17,759 | 22.3% | 17,754 | 22.3% | ||
| Medicare | 198,056 | 26.2% | 161,632 | 24.0% | 36,424 | 45.2% | 72,748 | 45.8% | 36,377 | 45.8% | 36,371 | 45.7% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 252,748 | 33.5% | 228,203 | 33.9% | 24,545 | 30.5% | <0.001 | 48,374 | 30.4% | 24,184 | 30.4% | 24,190 | 30.4% | 0.97 |
| Yes | 501,805 | 66.5% | 445,821 | 66.1% | 55,984 | 69.5% | 110,626 | 69.6% | 55,316 | 69.6% | 55,310 | 69.6% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 1.24 | 1.82 | 1.23 | 1.81 | 1.32 | 1.90 | <0.001 | 1.31 | 1.88 | 1.31 | 1.87 | 1.32 | 1.88 | 0.75 |
BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.